<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00337727</url>
  </required_header>
  <id_info>
    <org_study_id>0869-130</org_study_id>
    <secondary_id>2006_016</secondary_id>
    <nct_id>NCT00337727</nct_id>
  </id_info>
  <brief_title>Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Moderately Emetogenic Chemotherapy (MEC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The study will test aprepitant for the prevention of CINV in patients receiving their initial
      cycle of Moderately Emetogenic Chemotherapy (MEC). Patients receiving more then one cycle of
      chemotherapy may opt to participate in an optional second cycle during which the patient will
      receive the same antiemetic regimen as cycle 1, except that an IV formulation of aprepitant
      will be given in place of the oral formulation on study day one. Study drug administration on
      subsequent days will be given orally as in cycle 1.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2007</start_date>
  <completion_date type="Actual">November 19, 2008</completion_date>
  <primary_completion_date type="Actual">October 28, 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Reported No Vomiting</measure>
    <time_frame>Overall phase (0-120 hours post initiation of MEC) in Cycle 1.</time_frame>
    <description>The number of patients who reported No Vomiting in the overall phase in Cycle
1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Reported Complete Response</measure>
    <time_frame>Overall phase (0-120 hours post initiation of MEC) in Cycle 1</time_frame>
    <description>The number of patients who reported Complete Response (no vomiting and no use of rescue medication) in the overall phase in Cycle 1.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">848</enrollment>
  <condition>Chemotherapy-Induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 1: Day 1: aprepitant 125 mg capsule; ondansetron 8 mg capsule prior to chemotherapy and 1 8mg capsule 12 hrs after first dose; dexamethasone 12 mg tablets + 2 dexamethasone Pbo tablets. Day 2: Aprepitant 80 mg capsule; Ondansetron 8 mg capsule every 12 hours Day 3: Aprepitant 80 mg capsule Ondansetron 8 mg capsule every 12 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm 2: Day 1: Aprepitant 125 mg Pbo capsule; Ondansetron 8 mg capsule prior to chemotherapy and 8 mg capsule 12 hours after first dose; Dexamethasone 20 mg tablets. Day 2: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours; Day 3: Aprepitant 80 mg Pbo capsule; Ondansetron 8 mg capsule every 12 hours. 3 Day treatment period Optional cycle 2 is being offered to patients. Optional cycle 2 will substitute aprepitant with fosaprepitant dimeglumine 115 mg or Pbo on day 1. All other dosing regimen will remain the same as cycle 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aprepitant</intervention_name>
    <description>aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MK0869</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: ondansetron</intervention_name>
    <description>Ondansetron 8 mg capsule Three day treatment period.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Zofran®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: dexamethasone</intervention_name>
    <description>dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>DEXAMETHASONE TABLETS USP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: fosaprepitant dimeglumine</intervention_name>
    <description>fosaprepitant dimeglumine 115 mg</description>
    <arm_group_label>2</arm_group_label>
    <other_name>EMEND®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator; Placebo (unspecified)</intervention_name>
    <description>dexamethasone 12mg Pbo tablets.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator; Placebo (unspecified)</intervention_name>
    <description>Aprepitant 80 mg &amp; 125 mg Pbo capsules.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients will be naive to emetogenic chemotherapy with histologically or cytologically
             confirmed malignant disease scheduled to receive a single dose of moderately
             emetogenic chemotherapy on study day 1

          -  Karnofsky score of 60 or greater

        Exclusion Criteria:

          -  Patient is scheduled to receive any dose of cisplatin

          -  Patient will receive abdominal or pelvic radiation a week prior and up to 6 days after
             initiation of chemotherapy

          -  Any allergies to study drug or antiemetics

          -  Taking CYP3A4 substrates/prohibited medication

          -  Significant medical or mental conditions

          -  Abnormal laboratory values (platelets, absolute neutrophils, AST, ALT, bilirubin or
             creatinine).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>(MedWatch - FDA maintained medical product safety Information)</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>(Merck: Patient &amp; Caregiver U.S. Product Web Site)</description>
  </link>
  <results_reference>
    <citation>Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010 Apr;18(4):423-31. doi: 10.1007/s00520-009-0680-9. Epub 2009 Jul 1.</citation>
    <PMID>19568773</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2006</study_first_submitted>
  <study_first_submitted_qc>June 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2006</study_first_posted>
  <results_first_submitted>September 30, 2009</results_first_submitted>
  <results_first_submitted_qc>September 30, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2009</results_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 58 investigative sites worldwide. The first patient entered the study on 16-Jan-
2007 and the last patient’s last visit was on 28-Oct-2008.</recruitment_details>
      <pre_assignment_details>Cancer patients naïve to both moderately and highly emetogenic chemotherapy (MEC and HEC, respectively) scheduled to receive an initial course of MEC for confirmed malignant disease. The study focused on patients receiving an initial cycle of MEC (Cycle 1).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aprepitant Regimen</title>
          <description>Aprepitant 125mg by mouth (PO) plus ondansetron 8mg PO twice daily and dexamethasone 12mg PO on Day 1 and aprepitant 80mg PO once daily on Days 2 and 3.</description>
        </group>
        <group group_id="P2">
          <title>Standard Regimen</title>
          <description>Ondansetron 8mg PO twice daily plus dexamethasone 20mg PO on Day 1 and ondansetron 8mg PO twice daily on Days 2 and 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="430"/>
                <participants group_id="P2" count="418"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="412"/>
                <participants group_id="P2" count="406"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aprepitant Regimen</title>
          <description>Aprepitant 125mg by mouth (PO) plus ondansetron 8mg PO twice daily and dexamethasone 12mg PO on Day 1 and aprepitant 80mg PO once daily on Days 2 and 3.</description>
        </group>
        <group group_id="B2">
          <title>Standard Regimen</title>
          <description>Ondansetron 8mg PO twice daily plus dexamethasone 20mg PO on Day 1 and ondansetron 8mg PO twice daily on Days 2 and 3.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="430"/>
            <count group_id="B2" value="418"/>
            <count group_id="B3" value="848"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.1" spread="11.8"/>
                    <measurement group_id="B2" value="55.9" spread="12.6"/>
                    <measurement group_id="B3" value="56.5" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="327"/>
                    <measurement group_id="B2" value="325"/>
                    <measurement group_id="B3" value="652"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="296"/>
                    <measurement group_id="B3" value="583"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multi-racial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Motion Sickness</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="405"/>
                    <measurement group_id="B2" value="376"/>
                    <measurement group_id="B3" value="781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Data – Assessment Not Completed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Vomiting with Pregnancy</title>
          <description>Measure is specific to the female study population.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                    <measurement group_id="B2" value="250"/>
                    <measurement group_id="B3" value="516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Applicable- Male Patients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Reported No Vomiting</title>
        <description>The number of patients who reported No Vomiting in the overall phase in Cycle
1</description>
        <time_frame>Overall phase (0-120 hours post initiation of MEC) in Cycle 1.</time_frame>
        <population>FAS (full analysis set) patient population was used for all efficacy evaluations and included patients who (1) received Moderately Emetogenic Chemotherapy (MEC), (2) took a dose of study drug, and (3) completed at least one post treatment efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Aprepitant Regimen</title>
            <description>Aprepitant 125mg by mouth (PO) plus ondansetron 8mg PO twice daily and dexamethasone 12mg PO on Day 1 and aprepitant 80mg PO once daily on Days 2 and 3.</description>
          </group>
          <group group_id="O2">
            <title>Standard Regimen</title>
            <description>Ondansetron 8mg PO twice daily plus dexamethasone 20mg PO on Day 1 and ondansetron 8mg PO twice daily on Days 2 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Reported No Vomiting</title>
          <description>The number of patients who reported No Vomiting in the overall phase in Cycle
1</description>
          <population>FAS (full analysis set) patient population was used for all efficacy evaluations and included patients who (1) received Moderately Emetogenic Chemotherapy (MEC), (2) took a dose of study drug, and (3) completed at least one post treatment efficacy assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>Superiority based on 2-sided level of significance of 0.05, based on a logistic regression model that included terms for treatment group, region and gender.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Reported Complete Response</title>
        <description>The number of patients who reported Complete Response (no vomiting and no use of rescue medication) in the overall phase in Cycle 1.</description>
        <time_frame>Overall phase (0-120 hours post initiation of MEC) in Cycle 1</time_frame>
        <population>FAS (full analysis set) patient population was used for all efficacy evaluations and included patients who (1) received MEC, (2) took a dose of study drug, and (3) completed at least one post treatment efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Aprepitant Regimen</title>
            <description>Aprepitant 125mg by mouth (PO) plus ondansetron 8mg PO twice daily and dexamethasone 12mg PO on Day 1 and aprepitant 80mg PO once daily on Days 2 and 3.</description>
          </group>
          <group group_id="O2">
            <title>Standard Regimen</title>
            <description>Ondansetron 8mg PO twice daily plus dexamethasone 20mg PO on Day 1 and ondansetron 8mg PO twice daily on Days 2 and 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Reported Complete Response</title>
          <description>The number of patients who reported Complete Response (no vomiting and no use of rescue medication) in the overall phase in Cycle 1.</description>
          <population>FAS (full analysis set) patient population was used for all efficacy evaluations and included patients who (1) received MEC, (2) took a dose of study drug, and (3) completed at least one post treatment efficacy assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="425"/>
                <count group_id="O2" value="407"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292"/>
                    <measurement group_id="O2" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>Superiority based on 2-sided level of significance of 0.05, based on a logistic regression model that included terms for treatment group, region and gender.</p_value_desc>
            <method>Regression, Logistic</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Aprepitant Regimen</title>
          <description>Aprepitant 125mg by mouth (PO) plus ondansetron 8mg PO twice daily and dexamethasone 12mg PO on Day 1 and aprepitant 80mg PO once daily on Days 2 and 3.</description>
        </group>
        <group group_id="E2">
          <title>Standard Regimen</title>
          <description>Ondansetron 8mg PO twice daily plus dexamethasone 20mg PO on Day 1 and ondansetron 8mg PO twice daily on Days 2 and 3.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Ileitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Peripheral Ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Superior Vena Cava Occlusion</sub_title>
                <description>Superior Vena Cava Occlusion</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 11.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="265" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="270" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="430"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

